Simulations Plus Inc
NASDAQ:SLP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Simulations Plus Inc
Gross Profit
Simulations Plus Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Simulations Plus Inc
NASDAQ:SLP
|
Gross Profit
$49.9m
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Gross Profit
$2.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
18%
|
CAGR 10-Years
25%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Gross Profit
$778.8m
|
CAGR 3-Years
32%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Gross Profit
$514.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Omnicell Inc
NASDAQ:OMCL
|
Gross Profit
$508m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Gross Profit
$751.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Simulations Plus Inc
Glance View
Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.
See Also
What is Simulations Plus Inc's Gross Profit?
Gross Profit
49.9m
USD
Based on the financial report for Feb 28, 2026, Simulations Plus Inc's Gross Profit amounts to 49.9m USD.
What is Simulations Plus Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
13%
Over the last year, the Gross Profit growth was 15%. The average annual Gross Profit growth rates for Simulations Plus Inc have been 4% over the past three years , 7% over the past five years , and 13% over the past ten years .
